


# **EXPRESSION ANALYSIS, FUNCTIONAL ENRICHMENT, AND NETWORK INFERENCE**

---

**John Quackenbush**  
Dana-Farber Cancer Institute  
Harvard T.H. Chan School of Public Health

## **Background and Disclosures**

- **Professor of Biostatistics and Computational Biology, Dana-Farber Cancer Institute**
- **Professor of Computational Biology and Bioinformatics, Harvard School of Public Health**
- **Many other academic titles**
- **Numerous advisory boards**
- **Co-Founder of Genospace, a Precision Genomic Medicine Software Company**



*Current Topics in Genome Analysis 2016*

*John Quackenbush*

*Genospace, LLC  
Co-Founder and Board Chair*



**Every revolution in science — from Copernican heliocentric model to the rise of statistical and quantum mechanics, from Darwin’s theory of evolution and natural selection to the theory of the gene — has been driven by one and only one thing: access to data.**


**—John Quackenbush**

**@johnquackenbush-Every revolution in the history science has been driven by one and only one thing: access to data.**

Twitter version, 115 characters with spaces

## **A Brief History of Expression Analysis**

## February 2001: Completion of the Draft Human Genome




Public HGP




Celera Genomics


## Molecular Biology in 7 Words





## The Genome Project has provided a “parts list” for a human cell



## Different cell types express different sets of genes







## Quantitative RT-PCR: The Ancient World

ORNL-DWG 9-1M-17476

### DNA Amplification Using Polymerase Chain Reaction





## Quantitative PCR





- Paired hybridization of two primers is the filter on the data
- Quantitation requires normalization (comparison to standard curves)
- Normalization is based on assumptions










# Experimental Overview

## Expression Analysis Pipeline: Microarrays



# Design the Experiment

## Why Design an Experiment?

- The goal of an experiment dictates everything from how the samples are collected to how the data are generated
- The design of the analytical protocol should be reflected in the design
  - Do we have enough replicates?
  - Do we have sufficient controls?
  - Do we collect samples and data to avoid confounding and batch effects?

## Basis of Experimental Design

- In biology, “traditional” approaches to inquiry involved hypothesis testing.
  - We identify a problem and postulate a mechanism
  - We design an experiment in which we perturb the system and then look for changes
  - The response of the system either validates or invalidates our hypothesis
- In these types of experiments, we attempt to tightly control the variables so as to carefully measure the influence of these, perturbing a single parameter at a time
- Good experimental design requires sufficient replication to estimate the effects we wish to measure

## Basis of Experimental Design

- Functional genomics technologies have dramatically changed the way in which we approach biological questions
  - We can now survey the responses of thousands of genes, proteins, or metabolites in a particular system and look for patterns of expression
  - These “hypothesis generating” experiments do not (necessarily) require a mechanistic hypothesis ahead of time
  - However, this does not mean we do not have to carefully design our experiment and analyze the data
- Here, we attempt to control the variables so as to carefully measure the influence of these, perturbing a single parameter at a time
- Good experimental design requires sufficient replication to estimate the effects we wish to measure

## Types of Experiments

- Class Comparison
  - Can I find genes that distinguish between two classes, such as tumor and normal?
- Class Discovery
  - Given what I think is a uniform group of samples, can I find subsets that are biologically meaningful?
- Classification
  - Given a set of samples in different classes, can I assign a new, unknown sample to one of the classes?
- Large-scale Functional Studies
  - Can I discover a causative mechanism associated with the distinction between classes?

These are often not completely distinct and a single dataset can often be used for multiple purposes


## Normalization

## Why Normalize Data?

- The goal of normalization is to remove systematic variation from the data and scale it so that comparisons can be made across studies

## RMA Background correction


- Expression = Background ( $N(0, \sigma^2)$ ) + Signal ( $\text{Exp}(\alpha)$ )



## RMA Normalization

- Force the empirical distribution of probe intensities to be the same for every chip in an experiment
- The common distribution is obtained by averaging each *quantile* across chips:  
*Quantile Normalization*

## One distribution for all arrays: the black curve






## RMA: Probe set summary


- Robustly fit a two-way model yielding an estimate of  $\log_2(\text{signal})$  for each probe set
- Fit may be by
  - median polish (quick) or by
  - Mestimation (slower but yields standard errors and good quality)
- RMA reduces variability without losing the ability to detect differential expression

## RMA: Before and After

Boxplot and histogram of signal intensities before RMA pre-processing




Boxplot and histogram of signal intensities after RMA pre-processing




<http://www.slideshare.net/wijessen/covance-talk>

## Ratio-Intensity: Before




## Ratio-Intensity: After



## Normalization

- There are many, many methods
- All attempt to do the same thing, but all have their own assumptions that may or may not be violated
- RMA is widely accepted as the standard for microarrays
- There is less consensus on what works best for RNA-seq
- We constantly have to test our assumptions, even with normalization


## GTEX: Complex data requires complex methods






# Clustering: Finding Patterns

## Hierarchical Clustering

1. Calculate the distance between all genes. Find the smallest distance.  
If several pairs share the same similarity, use a predetermined rule to decide between alternatives.
2. Fuse the two selected clusters to produce a new cluster that now contains at least two objects. Calculate the distance between the new cluster and all other clusters.
3. Repeat steps 1 and 2 until only a single cluster remains.
4. Draw a tree representing the results.







### Agglomerative Linkage Methods

Linkage methods are rules or metrics that return a value that can be used to determine which elements (clusters) should be linked.

Three linkage methods that are commonly used are:

- Single Linkage
- Average Linkage
- Complete Linkage

(HCL6)

## Single Linkage

Cluster-to-cluster distance is defined as the *minimum distance* between members of one cluster and members of the another cluster. Single linkage tends to create 'elongated' clusters with individual genes chained onto clusters.

$$D_{AB} = \min ( d(u_i, v_j) )$$

where  $u \in A$  and  $v \in B$   
for all  $i = 1$  to  $N_A$  and  $j = 1$  to  $N_B$



(HCL7)

## Average Linkage

Cluster-to-cluster distance is defined as the *average distance* between all members of one cluster and all members of another cluster. Average linkage has a slight tendency to produce clusters of similar variance.

$$D_{AB} = 1/(N_A N_B) \sum \sum ( d(u_i, v_j) )$$

where  $u \in A$  and  $v \in B$   
for all  $i = 1$  to  $N_A$  and  $j = 1$  to  $N_B$



(HCL8)

## Complete Linkage

Cluster-to-cluster distance is defined as the *maximum distance* between members of one cluster and members of the another cluster. Complete linkage tends to create clusters of similar size and variability.


$$D_{AB} = \max ( d(u_i, v_j) )$$

where  $u \in A$  and  $v \in B$   
for all  $i = 1$  to  $N_A$  and  $j = 1$  to  $N_B$



(HCL9)

## Comparison of Linkage Methods







49

## K-means/K-medians Clustering (KMC)

1. Specify number of **clusters**, e.g., 5.




2. Randomly assign genes to clusters.



50

## KMC, continued

3. Calculate mean / median expression profile of each cluster.
4. Select a gene and move it to the cluster having the closest mean profile.



5. If the gene is shifted to a new cluster, recalculate means for the winning and losing clusters.
6. Repeat steps 4 and 5 until genes cannot be shuffled around any more, OR a userspecified number of iterations has been reached.

*k*means is most useful when the user has an *a priori* hypothesis about the number of clusters the genes should belong to.

# Finding Differentially Expressed Genes


## Lies, Damn Lies, and Statistics

### Finding Significant Genes



#### t-test for each gene

- Tests whether the difference between the mean of the query and reference groups are the same
- Essentially measures signal-to-noise
- Calculate  $p$ -value (permutations or distributions)
- May suffer from intensity-dependent effects

$$t = \frac{\text{signal}}{\text{noise}} = \frac{\text{difference between means}}{\text{variability of groups}} = \frac{\langle X_q \rangle - \langle X_c \rangle}{\text{SE}(X_q X_c)}$$



$$t = \frac{\langle X_q \rangle - \langle X_c \rangle}{\sqrt{\frac{\sigma_q^2}{n_q} + \frac{\sigma_c^2}{n_c}}}$$



## **Biological Interpretation**

**What do the genes in  
this list do?**

**Tell me a story, Grampa**


### **Biological Interpretation**

- An obvious way to gain biological insight is to assess the differentially expressed genes in terms of their known function(s)
- Requires an automated and objective (statistical) approach
- Functional profiling or pathway analysis

## Early functional analyses

- Manually annotate list of differentially expressed (DE) genes
- Extremely time-consuming, not systematic, user-dependent
- Group together genes with similar function
- Conclude functional categories with most DE genes important in disease/condition under study
- BUT... it may not be the right conclusion
- This is what we call “Biopoetry.”

## GO and functional analysis



Functional category	Number of sig genes
Immune response	40
Metabolism	20
Transcription	20
Energy production	10
Neurotransmission	5
Protein transport	5
<b>TOTAL</b>	<b>100</b>

Immune response category contains 40% of all significant genes - by far the largest category.

Reasonable to conclude that immune response may be important in the condition being studied?

## However ...

- What if 40% of the genes on the array were involved in immune response?
- Only detected as many significant immune response genes as expected by chance
- Need to consider not only the number of significant genes for each category, but also total number on the array

## Same example, relative to background

Functional category	Number of genes on array	Observed number of significant genes	Expected number of significant genes
Immune response	8000	40	40
Metabolism	4000	20	20
Transcription	2000	10	10
Energy production	4000	30	20
Neurotransmission	200	5	1
Protein transport	1800	5	9
ALL	20000	100	



Expected number of significant genes for category X is  
 $(\text{num sig genes} \div \text{total genes on array}) * (\text{num genes in category X on array})$

## Same example, relative to background

Functional category	Number of genes on array	Observed number of significant genes	Expected number of significant genes
Immune response	8000	40	40
Metabolism	4000	20	20
Transcription	2000	10	10
Energy production	4000	30	20
Neurotransmission	200	5	1
Protein transport	1800	5	9
ALL	20000	100	

- Now, energy production and neurotransmission categories appear more interesting as many more significant genes were observed than expected by chance
- Largest categories are not necessarily the most interesting!

**DAVID Bioinformatics Resources 6.7**  
 National Institute of Allergy and Infectious Diseases (NIAID), NIH

Home | Start Analysis | Shortcut to DAVID Tools | Technical Center | Downloads & APIs | Terms of Service | Why DAVID? | About Us

**Shortcut to DAVID Tools**

- Functional Annotation**  
Gene annotation enrichment analysis, functional annotation clustering, Biocarta & KEGG pathway mapping, gene-disease association, hierarchical match, 2D translation, literature match and more
- Gene Functional Classification**  
Provide a rapid means to reduce large lists of genes into functionally related groups of genes to help control the biological context of biological data
- Gene ID Conversion**  
Convert list of gene IDs/accessions to others of your choice with the most comprehensive gene ID mapping repository. The analogous accessions in the list can also be determined automatically. [More](#)
- Gene Name Batch Viewer**  
Display gene names for a given gene list. Search functionally related genes with your list or not in your list. Deep links to enriched related information. [More](#)

Recommending: [A paper published in Nature Protocols](#) describes step-by-step procedure to use DAVID!

**Welcome to DAVID 6.7**

2003 - 2016

The Database for Annotation, Visualization and Integrated Discovery (DAVID) v6.7 is an update to the sixth version of our original web-accessible program. DAVID now provides a comprehensive set of functional annotation tools for investigators to understand biological meaning behind large lists of genes. For any given gene list, DAVID tools are able to:

- Identify enriched biological themes, particularly GO terms
- Discover enriched functional related gene groups
- Cluster redundant annotation terms
- Visualize genes on Biocarta & KEGG pathway maps
- Display related many-genes-to-many-terms on 2-D view
- Search for other functionally related genes not in the list
- List interacting proteins
- Explore gene names in batch
- Link gene-disease associations
- Highlight protein functional domains and motifs
- Redirect to related literatures
- Convert gene identifiers from one type to another
- And more

**What's Important in DAVID?**

- [Current \(v. 6.7\) release note](#)
- [New requirement to cite DAVID](#)
- [IDs of Affy Exons and Gene arrays supported](#)
- [Novel Classification Algorithms](#)
- [Pre-built Affymetrix and Illumina backgrounds](#)
- [User's customized gene background](#)
- [Enhanced calculating speed](#)

**Statistics of DAVID**

DAVID Bioinformatic Resources Citations

- > 21,000 Citations**
- Average Daily Usage** ~2,600 gene lists/sublists from ~800 unique researchers
- Average Annual Usage** ~1,000,000 gene lists/sublists from >5,000 research institutes world-wide

Please cite [Nature Protocols 2009, 4\(1\):41 & \*Nucleic Acids Res.\* 2009, 37\(1\):1](#) within any publication that makes use of any methods inspired by DAVID.

leidos NHGRI ADPC NCI Frederick FIRST.GOV Department of Health and Human Services

[Term of Service](#) | [Contact Us](#) | [Site Map](#)

<https://david.ncifcrf.gov/>

**Gene Set Enrichment Analysis (GSEA)** is a computational method that determines whether a priori defined set of genes shows statistically significant, concordant differences between two biological states (e.g. phenotypes).

From this web site, you can:

- Download the GSEA software and additional resources to analyze, annotate and interpret enrichment results.
- Explore the Molecular Signatures Database (MSigDB), a collection of annotated gene sets for use with GSEA software.
- View documentation describing GSEA and MSigDB.

**What's New**

29-Feb-2016: The Sunday 28-Feb-2016 maintenance is complete on the GSEA/MSigDB website. Thanks for your patience!

13-Jan-2016: Version 5.1 of the Molecular Signatures Database (MSigDB) is now available. It includes the addition of 2,962 gene sets to the C7 collection of immunologic signatures, as well as a number of updates and corrections. See the Release Notes for details.

23-Dec-2015: Our paper describing the generation of the Hallmarks collection and examples of its use for GSEA was published in Cell Systems.

10-Dec-2015: We have confirmed that GSEA v2.2.0 and newer are compatible with Java 8 and produce equivalent results. Its use is highly recommended.

05-May-2015: Version 5.0 of the Molecular Signatures Database (MSigDB) is now available. It includes a new collection (H) of 50 hallmark signatures and a number of other additions and updates. See the MSigDB v5.0 Release Notes for details.

10-Jun-2014: In collaboration with the Bader Lab at the University of Toronto, we have added Enrichment Map visualizations as one of the steps in a GSEA analysis. See the GSEA v2.1.0 Release Notes for details.

**Registration**

Please register to download the GSEA software and view the MSigDB gene sets. After registering, you can log in at any time using your email address. Registration is free. Its only purpose is to help us track usage for reports to our funding agencies.

**Contributors**

GSEA and MSigDB are maintained by the GSEA team with the support of our MSigDB Scientific Advisory Board. Our thanks to our many contributors. Funded by: National Cancer Institute, National Institutes of Health, National Institute of General Medical Sciences.

**Citing GSEA**

To cite your use of the GSEA software, please reference Subramanian, Tamayo, et al. (2005, PNAS 102, 15545-15550) and Mootha, Lindgren, et al. (2003, Nat Genet 34, 267-273).

MSigDB Database v5.1 updated January 2016  
 GSEA/MSigDB web site v2.0 released March 2015

<http://software.broadinstitute.org/gsea/index.jsp>

# Gene Ontology

Gene Ontology Consortium

Search GO data

Enrichment analysis

Statistics

Highlighted GO term

Random FAQs

Recent news

Tweets

Copyright © 1999-2015 the Gene Ontology (CC-BY 4.0)  
 Helpdesk • Contact Us • Terms of Use • RSS  
 Member of the Open Biological and Biomedical Commons  
 The Gene Ontology Consortium is supported by a P41 grant from the National Human Genome Research Institute (NHGRI) (grant 5U41HG002273-16). The Gene Ontology Consortium would like to acknowledge the assistance of many more people than can be listed here. Please visit the acknowledgements page for the full list.



# KEGG pathway database

KEGG Home  
 Release notes  
 Current statistics  
 Plea from KEGG

KEGG Database  
 KEGG overview  
 Searching KEGG  
 KEGG mapping  
 Color codes

KEGG Objects  
 Pathway maps  
 Brite hierarchies

KEGG Software  
 KegTools  
 KEGG API  
 KGML

KEGG FTP  
 Subscription

GenomeNet  
 DBGET/LinkDB

Feedback  
 Kanehisa Labs

KEGG: Kyoto Encyclopedia of Genes and Genomes

KEGG is a database resource for understanding high-level functions and utilities of the biological system, such as the cell, the organism and the ecosystem, from molecular-level information, especially large-scale molecular datasets generated by genome sequencing and other high-throughput experimental technologies (See Release notes for new and updated features).  
 Please see: Renewed plea to support KEGG

New service  
 BlastKOALA for genome/metagenome annotation is now available. more ...

Main entry point to the KEGG web service  
 KEGG2 KEGG Table of Contents Update notes

Data-oriented entry points  
 KEGG PATHWAY KEGG pathway maps [Pathway list]  
 KEGG BRITE BRITE functional hierarchies [Brite list]  
 KEGG MODULE KEGG modules [Module list | Statistics] *New!*  
 KEGG ORTHOLOGY Ortholog groups [KO system | Annotation]  
 KEGG GENOME Genomes [KEGG organisms]  
 KEGG GENES Genes and proteins [Release history]  
 KEGG COMPOUND Small molecules [Compound classification]  
 KEGG REACTION Biochemical reactions [Reaction modules]  
 KEGG DISEASE Human diseases [Cancer | Infectious disease]  
 KEGG DRUG Drugs [ATC drug classification]  
 KEGG MEDICUS Health information resource [Drug labels search]

Organism-specific entry points  
 KEGG Organisms Enter org code(s)  Go hsa hsa eco

Analysis tools  
 KEGG Mapper KEGG PATHWAY/BRITE/MODULE mapping tools  
 KEGG Atlas Navigation tool to explore KEGG global maps  
 BlastKOALA *New!* New service for genome/metagenome annotation  
 BLAST/FASTA Sequence similarity search  
 SIMCOMP Chemical structure similarity search

Copyright 1995-2014 Kanehisa Laboratories

# WikiPathways

page discussion view source history

Log in / create account

WIKIPATHWAYS  
 Pathways for the People

Welcome to WikiPathways BETA  
 WikiPathways is an open, public platform dedicated to the curation of biological pathways by and for the scientific community. More about WikiPathways...

Finding Pathways

Search  
 You can search by:  
 Pathway name (Apoptosis)  
 Gene or protein name (p53)  
 Any page content (cancer)

Browse  
 Browse by species and category

Contributing New Pathways

Create  
 Create a new pathway page

Suggest  
 Add a pathway to the wish list

Sample Pathway Pages

Sandbox  
 Check out the following pages:  
 Show recent changes  
 Show new pathways  
 Show most edited pathways  
 Show most viewed pathways  
 Show pathway wish list  
 Selected publications using WikiPathways#

Today's Featured Pathway  
 Principle Pathways of Carbon Metabolism (Saccharomyces cerevisiae)

Latest discussions  
 Today  
 Data node types (1) by Martina Kutmon  
 13 November 2014  
 4 November 2014  
 D-threo-isocitrate (1) by Charles H. Bennett  
 more...

Forum  
 more...

Activity  
 Check out the WikiPathways poster presented at ISMB 2014 in Boston (Poster #)  
 Interactive pathway viewer. try it here!

67

# Pathway Commons

## For biologists

Search, visualize and download Pathway Commons pathways as part of an integrated network analysis ([more](#))

**Simple**  
See genes in pathway context

PCviz

**Advanced**  
See detailed processes

ChBE

**Analyze**  
Search and analyze pathway relationships

CyPath2

## For computational biologists and software developers

Download all pathways in BioPAX, SIF and other formats for pathway and network analysis. Build software on top of Pathway Commons using our web service API ([more](#))

**PC2: Web service**  
BioPAX Level 3, Advanced graph queries, Programmatic access, Batch downloads.

Pathway Commons 2

**BioPAX & Paxtools**  
Standard language for Biological Pathway Exchange and a software library for handling data in BioPAX.

BioPAX & Paxtools

**PaxtoolsR**  
An R interface for Paxtools software and Pathway Commons webservice.

PaxtoolsR

**PC: Previous web service**  
Obsolete, last updated 2011

Pathway Commons

# MSigDB

Gene Set Enrichment Analysis

**MSigDB Home**

- About Collections
- Browse Gene Sets
- Search Gene Sets
- Investigate Gene Sets
- View Gene Families
- Help

## Molecular Signatures Database v4.0

### Overview

The Molecular Signatures Database (MSigDB) is a collection of annotated gene sets for use with GSEA software. From this web site, you can:

- Search for gene sets by keyword.
- Browse gene sets by name or collection.
- Examine a gene set and its annotations. See, for example, the *AP002000* gene set page.
- Download gene sets.
- Investigate gene sets:
  - Compare overlaps between your gene set and gene sets in MSigDB.
  - Categorize members of a gene set by gene families.
  - View the expression profile of a gene set in any of the three provided public expression compendia.

### Registration

Please register to download the GSEA software and view the MSigDB gene sets. After registering, you can log in at any time using your email address. Registration is free. Its only purpose is to help us track usage for reports to our funding agencies.

### Current Version

MSigDB database v4.0 updated May 31, 2012. Release notes: [GSEA/MSigDB web site v4.0 released June 6, 2014](#)

### Contributors

The MSigDB is maintained by the GSEA team with the support of our MSigDB Scientific Advisory Board. We also welcome and appreciate contributions to the shared resource and encourage users to submit their gene sets to [gene\\_sets@broadinstitute.org](mailto:gene_sets@broadinstitute.org). Our thanks to our many contributors.

Funded by: National Cancer Institute, National Institutes of Health, National Institutes of General Medical Sciences.

### Collections

The MSigDB gene sets are divided into 7 major collections:

- C1 positional gene sets**: for each human chromosome and cytogenetic band.
- C2 curated gene sets**: from online pathway databases, publications in PubMed, and knowledge of domain experts.
- C3 motif gene sets**: based on conserved cis-regulatory motifs from a comparative analysis of the human, mouse, rat, and dog genomes.
- C4 computational gene sets**: defined by mining large collections of cancer-oriented microarray data.
- C5 GO gene sets**: consist of genes annotated by the same GO terms.
- C6 oncogenic signatures**: defined directly from microarray gene expression data from cancer gene perturbations.
- C7 immunologic signatures**: defined directly from microarray gene expression data from immunologic studies.

### Citing the MSigDB

To cite your use of the Molecular Signatures Database (MSigDB), please reference Subramanian, Tamayo, et al. (2005). *PLoS Biol* 3(10): e188 and also cite the source for the gene set as listed on the gene set page.


### Contact Us



If you have comments or questions, please contact us: [gene@broadinstitute.org](mailto:gene@broadinstitute.org).

# Biological Networks

## Can we make this more complicated?

### How NOT to do Network Analysis





## Starting Assumptions

- There is no single “right” network
- The structure of the network matters and network structure often changes between states.
- We have to move from asking “Is the network right?” to asking “Is the network useful?”
- The real question is “Does a network model inform our understanding of biology?”

## Modeling Gene Regulatory Networks

# Integrative Network Inference: PANDA

OPEN ACCESS Freely available online

PLOS ONE

## Passing Messages between Biological Networks to Refine Predicted Interactions


Kimberly Glass<sup>1,2</sup>, Curtis Huttenhower<sup>2</sup>, John Quackenbush<sup>1,2</sup>, Guo-Cheng Yuan<sup>1,2\*</sup>



<sup>1</sup> Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States of America, <sup>2</sup> Department of Biostatistics, Harvard School of Public Health, Boston, Massachusetts, United States of America

### Abstract

Regulatory network reconstruction is a fundamental problem in computational biology. There are significant limitations to such reconstruction using individual datasets, and increasingly people attempt to construct networks using multiple, independent datasets obtained from complementary sources, but methods for this integration are lacking. We developed PANDA (Passing Attributes between Networks for Data Assimilation), a message-passing model using multiple sources of information to predict regulatory relationships, and used it to integrate protein-protein interaction, gene expression, and sequence motif data to reconstruct genome-wide, condition-specific regulatory networks in yeast as a model. The resulting networks were not only more accurate than those produced using individual data sets and other existing methods, but they also captured information regarding specific biological mechanisms and pathways that were missed using other methodologies. PANDA is scalable to higher eukaryotes, applicable to specific tissue or cell type data and conceptually generalizable to include a variety of regulatory, interaction, expression, and other genome-scale data. An implementation of the PANDA algorithm is available at [www.sourceforge.net/projects/panda-net](http://www.sourceforge.net/projects/panda-net).

## Regulation of Transcription





# Subtypes of Ovarian Cancer

OPEN ACCESS Freely available online



## Angiogenic mRNA and microRNA Gene Expression Signature Predicts a Novel Subtype of Serous Ovarian Cancer


Stefan Bentink<sup>1,6,9</sup>, Benjamin Haibe-Kains<sup>1,6,9</sup>, Thomas Risch<sup>1</sup>, Jian-Bing Fan<sup>3</sup>, Michelle S. Hirsch<sup>4,7</sup>, Kristina Holton<sup>1</sup>, Renee Rubio<sup>1</sup>, Craig April<sup>3</sup>, Jing Chen<sup>3</sup>, Eliza Wickham-Garcia<sup>3</sup>, Joyce Liu<sup>2,7</sup>, Aedin Culhane<sup>1,6</sup>, Ronny Drapkin<sup>4,5,7</sup>, John Quackenbush<sup>1,2,6\*†</sup>, Ursula A. Matulonis<sup>5,7†</sup>

<sup>1</sup> Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States of America, <sup>2</sup> Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States of America, <sup>3</sup> Illumina, Inc., San Diego, California, United States of America, <sup>4</sup> Department of Pathology, Division of Woman's and Perinatal Pathology, Brigham and Women's Hospital, Boston, Massachusetts, United States of America, <sup>5</sup> Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States of America, <sup>6</sup> Harvard School of Public Health, Boston, Massachusetts, United States of America, <sup>7</sup> Harvard Medical School, Boston, Massachusetts, United States of America

### Abstract



Ovarian cancer is the fifth leading cause of cancer death for women in the U.S. and the seventh most fatal worldwide. Although ovarian cancer is notable for its initial sensitivity to platinum-based therapies, the vast majority of patients eventually develop recurrent cancer and succumb to increasingly platinum-resistant disease. Modern, targeted cancer drugs intervene in cell signaling, and identifying key disease mechanisms and pathways would greatly advance our treatment abilities. In order to shed light on the molecular diversity of ovarian cancer, we performed comprehensive transcriptional profiling on 129 advanced stage, high grade serous ovarian cancers. We implemented a re-sampling based version of the



# PANDA: Integrative Network Models



erly Glass, GC Yuan








## Complex Regulatory Patterns Emerge


TF1	TF2	sig.	#	Class	Co-regulatory TF Pairs
ARID3A	PRRX2	1.16E-23	244	A+	
ARID3A	SOX5	1.01E-14	155	A+	
PRRX2	SOX5	3.83E-12	157	A+	
ARNT	MZF1	5.83E-23	92	N-	
AHR	ARNT	6.13E-16	382	N-	
ETS1	MZF1	9.08E-16	148	N-	




Kimberly Glass, GC Yuan

## Regulatory Patterns suggest Therapies

### ANGIOGENIC BEHAVIOR



### TREATMENT MODEL



Kimberly Glass, GC Yuan

**RESEARCH ARTICLE**  
Glass et al. *BMC Bioinformatics* (2015) 16:115  
DOI 10.1186/s12859-015-0551-y

**RESEARCH ARTICLE**  
Glass et al. *BMC Systems Biology* 2014, 8:118  
<http://www.biomedcentral.com/1752-0509/8/118>

**RESEARCH ARTICLE** **Open Access**

**A network model of ovarian cancer**  
Kimberly Glass<sup>1,2,3</sup>, John Quackenbush<sup>1,2,3</sup>

**Sexually-dimorphic targeting of functionally-related genes in COPD**  
Kimberly Glass<sup>1,2,3\*</sup>, John Quackenbush<sup>1,2,3</sup>, Edwin K Silverman<sup>3,4</sup>, Bartolome Celli<sup>4</sup>, Stephen I Rennard<sup>5</sup>, Guo-Cheng Yuan<sup>1,3</sup> and Dawn L DeMeo<sup>3,4</sup>

**Abstract**  
**Background:** We recently identified mechanisms that distinguish the sub-model information flow in gene regulation. **Results:** We find distinct differences between subtypes, largely defined by a set of factors, are not strongly differentially expressed in their network. **Conclusions:** The models we develop suggest therapeutic targets between subtypes suggest therapeutic targets. **Keywords:** Network modeling, Gene regulation, Angiogenesis

**Abstract**  
**Background:** There is growing evidence that many diseases develop, progress, and respond to therapy differently in men and women. This variability may manifest as a result of sex-specific structures in gene regulatory networks that influence how those networks operate. However, there are few methods to identify and characterize differences in network structure, slowing progress in understanding mechanisms driving sexual dimorphism. **Results:** Here we apply an integrative network inference method, PANDA (Passing Attributes between Networks for Data Assimilation), to model sex-specific networks in blood and sputum samples from subjects with Chronic Obstructive Pulmonary Disease (COPD). We used a jack-knifing approach to build an ensemble of likely networks for each sex. By adapting statistical methods to compare these network ensembles, we were able to identify strong differential targeting patterns associated with functionally-related sets of genes, including those involved in mitochondrial function and energy metabolism. Network analysis also identified several potential sex- and disease-specific transcriptional regulators of these pathways. **Conclusions:** Network analysis yielded insight into potential mechanisms driving sexual dimorphism in COPD that were not evident from gene expression analysis alone. We believe our ensemble approach to network analysis provides a principled way to capture sex-specific regulatory relationships and could be applied to identify differences in gene regulatory patterns in a wide variety of diseases and contexts. **Keywords:** Network modeling, Gene regulation, Regulatory networks, Sexual-dimorphism, Chronic Obstructive Lung Disease

**More application papers coming....**

## At the End of the Day

- The goal of an experiment is to discover new biology
- The challenge is sorting through lots of data
- Comparing groups of samples requires thorough annotation
- Making sense of the genes that are significant in such a comparison requires thorough gene annotation
- New technologies are giving us new ways of generating data, but the analysis approaches are more-or-less the same.

**The future is here.  
It's just not widely distributed yet.**

**- William Gibson**

**Before I came here I was confused  
about this subject.  
After listening to your lecture,  
I am still confused but at a higher level.**

**- Enrico Fermi, (1901-1954)**